Participant flow

Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction · Source last updated 2013-09-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   The therapeutic potential of human immune globulin intravenous (IGIV)was evaluated in patients with cardiac-associated AL amyloidosis. Patients received, via intravenous infusion, 30-40 gm of IGIV (depending on body weight) weekly for 3 months and then every other week for the next 9 months.The total time to complete the study was \~1 yr.

   id

   FG000

   title

   Human Immune Globulin Intravenous (IGIV)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Physician Decision

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Lost to Follow-up

   3. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Protocol Violation

   4. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      death (not related to study)

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         10

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         2

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         8

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Patients with primary light-chain (AL)-associated amyloidosis that caused heart dysfunction were on study.

recruitment Details

Overall study length - 2007-2011; Location - medical clinic

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice